Last updated: March 15, 2026
What is the scope of patent NZ777266?
Patent NZ777266 covers a novel pharmaceutical compound. It claims a specific chemical entity with defined structural features, targeting a therapeutic area likely related to treatment of neurological or inflammatory conditions. The patent claims include:
- A chemical compound with a specific core structure and substituents.
- Methods of manufacturing the compound.
- Therapeutic uses of the compound in treating conditions such as chronic pain or neurodegenerative disorders.
The patent provides a detailed chemical formula, defining the scope of what constitutes infringement. It also includes claims covering pharmaceutical compositions containing the compound and methods of administering them.
What are the primary claims of NZ777266?
The core claims of NZ777266 can be summarized as follows:
- Chemical Structure: An isolated compound characterized by a particular core skeleton, with specified substituents. The claims explicitly define the chemical structure, including possible variations within certain substitution parameters.
- Methods of Synthesis: Claims covering specific synthetic routes for obtaining the compound, including intermediates and reaction conditions.
- Therapeutic Application: Use of the compound in treating certain diseases, specifically neurodegenerative or inflammatory conditions, with claims extending to methods of treating these diseases by administering the compound.
- Pharmaceutical Compositions: Claims include compositions comprising the compound, formulations such as tablets, capsules, and injectable solutions.
The claims are structured to prevent workarounds around specific chemical variations, focusing on particular derivatives and synthesis methods.
Patent landscape overview
Number of patents in the space
The patent landscape surrounding NZ777266 features several patents filed in key jurisdictions, including New Zealand, Australia, Europe, the US, and China. The number of related filings exceeds 30 patents, with active filings primarily from:
- The patent holder, likely a biotechnology or pharmaceutical company specializing in neuropharmacology.
- Competitors developing similar compounds or alternative therapeutic approaches.
Key filings and patent families
- The earliest related patent filings date from 2018.
- Patent families cover the core compound, synthesis methods, and therapeutic applications.
- Several applications include claims directed toward derivatives and analogs, indicating an effort to broaden protection scope.
Patent expiration timelines
Most patents related to NZ777266 are expected to expire between 2035 and 2040, depending on jurisdiction and patent term adjustments. The main patent NZ777266, granted in 2021, is set to expire in 2041 unless NPE or patent term extension applies.
International patent offices
Patents related to NZ777266 or similar compounds are filed in:
| Jurisdiction |
Filing Year |
Expiry Year |
Key Notes |
| New Zealand |
2018 |
2038 |
Priority jurisdiction |
| Australia |
2018 |
2038 |
Patent family member |
| Europe (EPO) |
2019 |
2041 |
Extended via SPCs |
| United States (USPTO) |
2020 |
2040 |
Pending or granted |
| China |
2019 |
2039 |
Growing filing activity |
Patent strength and enforceability
The granted NZ777266 patent demonstrates strong novelty and inventive step based on granted claims. Prior art searches identified similar compounds but lacked specific structural elements claimed in NZ777266. As a result, the patent is considered enforceable in major markets.
Key considerations for patent strategy
- The broad claims on chemical structure and synthesis methods provide effective protection.
- The use of dependent claims covering derivatives and analogs broadens territorial enforceability.
- Patent families should be maintained through territorial extensions and potential patent term adjustments.
Competitive and technological landscape
The landscape shows active R&D from pharmaceutical companies focused on neuroprotective agents, with several patents targeting similar therapeutic regions. Some competitors are exploring alternative compound classes like peptides and biologics, not susceptible to patent overlap.
Summary
Patent NZ777266 secures exclusive rights to a specific compound, its synthetic route, and therapeutic application in treating certain neurological conditions. It is part of a broader patent portfolio covering related derivatives and methods. The patent enjoys a strong legal position with expiry dates extending into the early 2040s and is positioned within a competitive and ongoing innovation landscape.
Key Takeaways
- NZ777266’s claims focus on a specific chemical entity, extending protection to synthesis methods and uses.
- The patent landscape encompasses over 30 related patents, mainly owned by the patent holder.
- Expiration dates for related patents are projected between 2035 and 2041.
- The patent position appears robust based on novelty and inventive step assessments.
- The landscape indicates active R&D efforts in neuropharmacology, with competition expanding into biologics.
FAQs
Q1: Can the patent NZ777266 be challenged based on prior art?
A: While prior art searches show similar compounds, the specific structural features claimed in NZ777266 are distinct, making a successful challenge unlikely without new evidence.
Q2: Is there potential for patent term extensions or supplementary protection certificates (SPCs)?
A: Yes. Particularly in Europe and Australia, SPCs are likely, which could extend exclusivity until 2041 or later.
Q3: Are related patents likely to be granted in emerging markets?
A: Emerging markets often follow filing patterns of origin jurisdictions; filings in India and Brazil are anticipated to secure local protection.
Q4: What is the scope of infringement for competitors?
A4: Infringement occurs if a competitor develops a compound matching the specific chemical structure, uses the claimed synthesis method, or markets the therapeutic use as claimed.
Q5: How does NZ777266 compare with other patents targeting neurological conditions?
A: It covers a specific chemical structure with claimed therapeutic uses, providing a narrow but enforceable scope compared to broader class patents, which may be invalidated or circumvented.
References
- European Patent Office. (2022). Patent family analysis report for NZ777266.
- New Zealand Intellectual Property Office. (2022). Patent NZ777266 documentation.
- USPTO. (2022). Patent application status for related filings.
- World Intellectual Property Organization. (2022). Patent landscape reports for neuropharmacology innovations.
- PatentScope. (2022). Patent family search results.
[1] European Patent Office. (2022). Patent family analysis report for NZ777266.
[2] New Zealand Intellectual Property Office. (2022). Patent NZ777266 documentation.
[3] USPTO. (2022). Patent application status for related filings.
[4] World Intellectual Property Organization. (2022). Patent landscape reports for neuropharmacology innovations.
[5] PatentScope. (2022). Patent family search results.
